Lilly CEO Dave Ricks Highlights Growth of Foundayo Oral Weight Loss Pill
Eli Lilly's CEO, Dave Ricks, stated that the company’s oral weight loss drug, Foundayo, now accounts for one in three new prescriptions in the U.S. market and is gaining traction weekly. Speaking to CNBC, he expressed confidence in Lilly's long-term position within this segment as expansion plans into additional countries are set for later 2026. Lilly recently broke ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030 and will produce components across multiple therapeutic areas including cardiometabolic health and oncology. Foundayo generated $98 million in Q2 revenue after its April U.S. launch. The drug's expansion into the UK via private prescriptions at a lower price point than Lilly’s injectable Mounjaro is also underway, while EU regulatory approval remains pending.
Topics: Manufacturing Investment Pharmaceuticals Weight Loss Drugs